Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...
Main Authors: | Juliana Park, Sophia Archuleta, May-Lin Helen Oh, Lynette Pei-Chi Shek, Hao Wang, Matthew Bonaparte, Carina Frago, Alain Bouckenooghe, Frederique Jantet-Blaudez, Sarah Begue, Sophie Gimenez-Fourage, Anke Pagnon |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-07-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2020.1861875 |
Similar Items
-
Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series
by: Juliana Park, et al.
Published: (2020-03-01) -
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials
by: Ngoc Huu Tran, et al.
Published: (2019-10-01) -
Safety of dengue vaccine (CYD-TDV) in Asia: a systematic review
by: W. R. Wan Ismail, et al.
Published: (2021-06-01) -
Hidden heterogeneity and its influence on dengue vaccination impact
by: Magdalene Walters, et al.
Published: (2020-01-01) -
Predictors of Booster Response to Hepatitis B Vaccine at 15 years of age: A Cross-Sectional School-Based Study
by: Yu-Sheng Chen, et al.
Published: (2016-08-01)